Viking Therapeutics Catapults 121% As Weight-Loss Drug Beats Out Lilly's Zepbound
In this article:
A weight-loss drug from Viking topped Lilly's Zepbound in a midstage study Tuesday. Viking stock more than doubled, while Lilly shares fell.
Advertisement